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Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient 
selection, follow-up and monitoring, reclassification, and which outcome measures should be 
prioritised.  
Objective: To develop consensus statements for all domains of DAT. Design, setting and participants: 
A protocol-driven, 3-phase study undertaken by the EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer 
Guideline Panel in conjunction with partner organisations, including: (1) A systematic review to 
describe heterogeneity across all domains; (2) A 2-round Delphi survey involving a large, international 
panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) A consensus 
group meeting attended by stakeholder group representatives. Robust methods regarding what 
constituted consensus were strictly followed.  
Results and limitations: 109 HCPs and 16 patients completed both survey rounds. Of 129 statements 
in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and 
voted on in the consensus meeting by 32 HCPs and 3 patients, where consensus was achieved in an 
additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some 
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uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low 
risk disease, and the role of mpMRI in determining disease stage and aggressiveness as a criterion for 
inclusion and exclusion.  
Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical 
practice and research, until higher levels of evidence emerge through prospective comparative studies 
and clinical trials.  
Patient summary: We undertook a project aimed at standardising elements of practice in active 
surveillance programmes for early localised prostate cancer because currently there is great variation 
and uncertainty regarding how best to conduct them. The project involved large numbers of 
healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve 





Deferred treatment with curative intent (i.e. deferred active treatment, or DAT) has emerged as a 
feasible alternative to standard radical interventions for low-risk localised prostate cancer. [1-3] This 
includes active surveillance or active monitoring, whereby patients are not curatively treated 
immediately but instead are reassessed and monitored at regular intervals, and involves a choice by a 
patient following counselling with their physician, and alternative treatment options may be 
considered at a future timepoint. Large, prospective studies are currently underway and medium-term 
outcomes appear to be promising. [4, 5] However, clinical practice guidelines (CPGs) [6] often 
acknowledge the significant heterogeneity inherent in deferred treatment strategies, with protocols 
differing in patient eligibility, selection and recruitment, disease monitoring and reassessment, 
outcome definition and measurement, and triggers for reclassification and change in management. In 
short, there is uncertainty regarding the definition of eligible patients, and the optimum follow-up 
strategies. Although attempts have been made to standardise definitions and terminology via 
consensus methods, [7] there have been no successful projects which harness clinical and patient 
expertise aiming to comprehensively standardise practice.  
Consequently, the EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel in conjunction with 
partner organisations (Appendix 1) commissioned and undertook a project to develop consensus 
statements for DAT. The project was unique and novel in its use of protocol-driven consensus 
methods. [8] The specific objectives were to achieve consensus on the following domains: (1) Criteria 
for patient selection, inclusion and exclusion; (2) Nature and timing of investigations and assessments 
during monitoring and follow-up; (3) Criteria and thresholds for reclassification and change in 
management; and (4) Type of outcome measures which should be prioritised. The study findings will 
be incorporated into international CPGs issued by the EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer 
Guideline Panel and collaborators, and will guide and inform clinical practice and further research. 
 
2. Material and Methods 
The protocol outlining the detailed methods underpinning the project has been published. [8] An 
overview of the study is depicted in Figure 1. The project was divided into 3 phases, lasting 12 months. 
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Phase 1 was a systematic review of current DAT practice [9] the results of which are summarized in 
Table 1 and Supplementary Table 1. The review findings were used to inform a list of statements and 
organised into domains and sub-domains reflecting aspects of DAT (i.e. patient eligibility and 
recruitment, follow-up and monitoring, reclassification, and outcome measures).  
In Phase 2, the list of statements was incorporated into an online questionnaire as part of a two-round 
iterative Delphi survey.  An international panel of participants including healthcare practitioners (i.e. 
urologists, medical and clinical/radiation oncologists, radiologists, pathologists, and specialist nurses) 
and patients were purposefully sampled to participate. The list of   organisations which participated is 
included in Appendix 1. These organisations were targeted owing to the expertise of their 
membership. Organisations provided participants by either nominating individuals or cascading the 
invitation to their entire membership. Informed consent was assumed if participants registered and 
completed the survey. 
In the online questionnaire, participants were presented with statements and asked to rate their 
strength of agreement on a scale of 1 (strongly disagree) to 9 (strongly agree). Participants could also 
suggest additional statements for incorporation into the following round. In Round 2, participants 
were provided with information regarding their own score from Round 1 as well as a summary of the 
scores for the entire cohort, and could either revise or retain their original scores. Thresholds 
regarding what constituted ‘consensus agreement’ and ‘consensus disagreement’ were specified a 
priori [8]. ‘Consensus agreement’ was defined as ≥70% of participants scoring a statement as ‘strongly 
agree’ (7-9) and <15% of participants scoring ‘strongly disagree’ (1-3). Conversely, ‘Consensus 
disagreement’ was defined as statements scored as ’strongly disagree’ (score 1–3) by ≥70% of 
participants and <15% of participants scoring ’strongly agree’ (7–9). All other statements not falling in 
the above categories will be classified as equivocal. The decision to use 70% as a threshold was based 
on prior studies and consensus methods research. [10-13] 
Phase 3 consisted of a one-day, face-to-face consensus group meeting attended by representatives 
from all stakeholder groups and chaired by a non-voting clinician and non-voting methodologist. 
Participants were sampled from those who completed both rounds of the Delphi survey. All 
participants were provided with a personalised print-out containing a reminder of how they scored 
each statement in both rounds of the Delphi, and were given the summary of group results for all 
statements. All statements not achieving consensus in Phase 2 were discussed, reviewed and voted 
upon by participants, using the same consensus thresholds from Phase 2, using live voting software 
[8]. At the end of Phase 3, a final list of consensus statements organised according to the domains of 
DAT were ratified by the consensus group participants and project steering group.  
 
3. Results 
3.1 Delphi survey 
Round 1 of the Delphi survey was generated from the systematic review findings (Appendix 2).  127 
statements were organised under the following domains and sub-domains: (1) Patient eligibility, 
inclusion and exclusion criteria: (a) Age and life expectancy; (b) Risk classification (including D’Amico 
or EAU risk groups, PSA elements, Gleason sum score/ISUP Grade group, clinical stage, etc.); (c) 
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Histopathological characteristics (including how biopsy is performed, extent of disease, etc.); and (d) 
Imaging characteristics (including issues regarding multi-parametric MRI, etc.); (2) Monitoring and 
follow-up criteria (including issues regarding frequency and nature of PSA testing, repeat biopsy, 
clinical examination by digital rectal examination, and imaging); (3) Reclassification and change in 
management criteria and triggers: (a) Patient characteristics; (b) PSA kinetics; (c) Histopathology 
(including change in grade or disease extent); (d) Clinical examination; (e) Imaging; and (f) Patient 
preference; and (4) Outcome measures which must be prioritised in DAT programmes (including 
oncological, functional and quality of life [QoL] outcomes).  
A total of 180 healthcare practitioners (HCPs) involved with DAT were identified through international 
specialist societies (Appendix 1) and invited to participate. 50 patients identified through patient 
advocacy organisations (Appendix 1) were invited to complete the patient-relevant parts of the survey 
(i.e. outcome measures which should be prioritised). Two additional statements suggested by 
participants were added to the questionnaire in Round 2 (Appendix 2), bringing the total number of 
statements to 129. In total, 126 HCPs (70% of those invited) and 29 patients (58% of those invited) 
completed Round 1, and 109 HCPs (61% of those invited) and 17 patients (34% of those invited) 
completed both rounds of the survey. The attrition rates between Rounds 1 and 2 were 14% for HCPs, 
and 41% for patients. Appendix 3 outlines the list of Delphi participants organised by stakeholder 
group (i.e. HCPs or patients), and including details such as name, speciality and country of residence 
for HCPs, and previous treatment, age and country of residence for patients.  
Table 2 summarises the characteristics of all Delphi participants completing both rounds of the survey, 
based on stakeholder groups, speciality (or relevant treatment for patients), age (for patients only) 
and country of residence. Table 3 summarises the survey results for all statements, organised 
according to consensus status (i.e. consensus, near consensus, divergent opinions, or 
equivocal/unclear). In summary, there was consensus on 66 statements (51%) from the Delphi survey. 
The other remaining 63 statements were brought forward for review, discussion and voting in Phase 
3, to see if consensus could be achieved on them.  
 
3.2 Consensus group meeting 
The consensus group meeting was held in Amsterdam on 9th November 2018 during the 10th 
European Multidisciplinary Congress on Urological Cancers (i.e. EMUC 2018). The meeting was 
attended by 35 voting participants (32 HCPs and 3 patients) and chaired by a non-voting clinician and 
a non-voting methodologist. Table 4 summarises the characteristics of consensus meeting participants 
based on stakeholder group, speciality and country of residence. Table 5 summarises the results for 
all statements reviewed, discussed and voted upon, organised according to consensus status ‘yes/no’ 
(i.e in summary, 27/63 statements (43%) achieved consensus during the meeting. 
 
3.3 Final consensus statements and recommendations from DETECTIVE Study 
Table 6 summarises all the consensus statements obtained from all phases of the study. In total, 93 
statements out of a total 129 (72%) achieved full consensus. The majority of these were achieved from 
the Delphi survey (71%), whilst the consensus group meeting contributed 29% to the consensus 
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statements. 53% of the consensus statements were ‘consensus agree’ whilst 48% were ‘consensus 
disagree’. Consensus was achieved in at least 65% of statements across all domains across the Delphi 




4.1 Principal findings 
This project explored and defined key areas of controversy and uncertainty covering all the main 
domains of deferred active treatment, a large undertaking not previously attempted on this scale 
using transparent methodology. A mixed methods approach was used to investigate this pressing 
problem, incorporating a systematic review, a two-round Delphi survey and a face-to-face consensus 
meeting with international participation from key stakeholders.  The systematic review confirmed the 
scale and scope of the problem, highlighting significant heterogeneity, inconsistency and variability in 
clinical practice across all domains in contemporary studies of DAT. Given such heterogeneity, it is not 
surprising to note that currently, there is no conclusive data on how different DAT strategies compare 
to one another, and which strategy, definition and threshold should be adopted in clinical practice, 
and in clinical trials. Although several seminal randomised controlled trials investigating the 
effectiveness of observation [1, 2]or active monitoring [3] as a management strategy for localised 
prostate cancer in comparison with active curative treatment have been published, these studies do 
not represent current practice of deferred active treatment, which has continued to evolve over the 
past 15 years, especially with the introduction of new technology such as mpMRI scan into the patient 
care pathway, changes in the reporting of prostate cancer grade, and more accurate ways of 
performing prostate biopsies (including MRI-targeted biopsies or transperineal template biopsies). 
There is, therefore, an urgent need to provide guidance to clinicians, patients, researchers and 
policymakers, and in the absence of high levels of evidence, the only available option is to issue 
consensus statements using robust, transparent and reproducible methods.  Our project set out to 
achieve this objective, and ultimately consensus was achieved in more than 72% of statements 
covering all the domains of DAT, and the results will provide the basis for international guidance and 
drive the research agenda for the immediate future. The main recommendations based on the 
consensus statements are listed in Table 7. 
 
4.2 Relevance and impact of study findings on clinical practice and research 
Our study, with participation from healthcare practitioners and patients, has provided the basis for 
conduct of DAT.  Consensus statements represent the lowest level of evidence (i.e. level 5) on the 
evidence-based medicine hierarchy, [14] but in areas where there is low certainty and conflicting 
evidence, they represent a pragmatic basis for interim guidance.  Consensus statements should be 
regarded as a starting point for clinicians and researchers to guide studies which will provide higher 
quality evidence and increase certainty. Evidence is never complete; it is ever-evolving, and 
correspondingly recommendations require updating as necessary.  Using our consensus statements 
as a basis for informing and guiding the conduct of DAT, there is a need for clinicians to prospectively 
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collect and audit data on DAT in routine clinical practice, and researchers and trialists to conduct 
clinical trials or prospective comparative studies so that clinical effectiveness data can be obtained. In 
this context, initiatives such as PIONEER [15] and the Movember Foundation’s Global Action Plan 
Active Surveillance (GAP3) project which aims to establish a global prospective database [16] 
represent important initial steps.       
Our results may be juxtaposed with those of other studies with overlapping aims.  Bruinsma et al. [7] 
used consensus methods to develop statements for active surveillance primarily aimed at 
standardising terms and definitions. The authors published a list of 61 items as a glossary of terms and 
definitions, whereas our study provides practical guidance for programmes of DAT.  Both studies are 
complementary.  MacLennan et al. [12] used similar consensus methods in creating a core outcome 
set applicable across all interventions, including deferred active treatment. The prioritised outcome 
measures obtained from our study (i.e. core outcomes for DAT) overlap with MacLennan et al.’s core 
outcome set, providing confidence that men with localised prostate cancer and the healthcare 
practitioners who treat them, regarded the same outcomes as important in two separate samples. 
More recently, Merriel et al. [17] published consensus statements on current best practice of active 
surveillance in the UK.  The statements were developed by a multi-disciplinary group of 27 members 
consisting of clinical experts and patient experts, informed by a review of the literature, existing 
guidelines and protocols used by UK Urology departments, and survey data from men with localized 
prostate cancer. The final consensus statements were then issued by a subgroup of the panel (n=14) 
at a face-to-face meeting.  There are clear similarities between both projects, with both being 
informed by a review of the literature, and statements were developed by a multidisciplinary panel of 
clinicians and patients covering similar domains. However, there are major differences. It was unclear 
if Merriel et al’s project was based on an a priori protocol for the systematic review (e.g. PRISMA) and 
for the consensus phases; the methods, processes and rules underpinning the consensus process, its 
definitions and how they were developed and achieved were not described. Our project was more 
international in scope, involved a larger multidisciplinary panel (n=125) and was protocol-driven. We 
believe these are essential elements in any consensus endeavour which minimise bias, arbitrariness 
and subjectivity, whilst enhancing rigour, transparency and reproducibility. Nevertheless, there is 
overlap between the findings of both projects across all domains, and there are no major contradictory 
findings; as such both projects could be regarded as complementary.   
 
4.3 Strengths and limitations 
The study used robust, transparent and reproducible methods based on an a priori protocol. The study 
was international and contemporary in scope, involving patients and a large panel of healthcare 
practitioners purposively sampled from a broad range of disciplines, all of whom are stakeholders in 
DAT. A two-step, multi-phase consensus building process based on an iterative Delphi survey and 
consensus group meeting using anonymous voting techniques was employed, all of which enhanced 
internal validity. High external validity was achieved by ensuring that the survey items were informed 
by a systematic review of the literature, which was undertaken according to PRISMA guidelines. In 
terms of limitations, the project was designed to be pragmatic and practical for participants. 
Statements had to be brief and concise, and although participants rated their judgements on a scale, 
decisions were essentially binary in nature (i.e. disagree or agree). Consequently, it was not possible 
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to address all elements of uncertainty regarding DAT. In particular, the decision-making process 
regarding patient inclusion or exclusion or reclassification often involves a complex interplay between 
multiple factors and variables. The relative weighting placed on each variable as one or more variables 
change within and across patients, and how this affects the decision-making process for patients and 
clinicians is difficult to conceptualise and address meaningfully in a consensus-finding study. Secondly, 
within the healthcare practitioners’ group, there was a higher ratio of urologists compared with other 
specialists, in both the Delphi survey and consensus group meeting. However, this reflects 
contemporary practice, whereby patients within DAT programmes are managed mostly by urologists. 
Additionally, there was an unusually high attrition rate within the patient group between Rounds 1 
and 2 of the Delphi survey (41%). However, the outcome of all statements rated by patients remained 
stable between Rounds 1 and 2, hence suggesting that the attrition had minimal impact on the 
consensus outcome. There is also a small risk of introducing sampling error in terms of failure to 
achieve a balance between contrasting attitudes regarding active surveillance. However, through 
purposive sampling of a large number and a wide range of clinical practitioners involved in active 
surveillance, diverse opinions regarding active surveillance would have been achieved and hence 
minimising this risk.  
The choice of a threshold for defining consensus (i.e. 70% in our study) merits a brief discussion. It 
may be argued that this is an arbitrary figure. However, our decision to use this threshold was 
informed by the methodological literature and through experience in previous consensus research 
conducted by members of the project steering group [12, 13, 18].  Many consensus projects define 
consensus as ≥70% of the participants choosing scores 7-9 and <15% choosing scores 1-3 (or vice 
versa) on a 9-point Likert scale, in order to account for the majority opinion whilst not dismissing 
divergent opinions [10, 11, 19].  The major emphasis in consensus methodology resources is that any 
threshold must have been judiciously selected, justified and described a priori [20, 21]. A higher 
threshold of 80% or 90% gives undue influence to outlier opinions and would have significantly 
reduced the number of items reaching consensus which seriously impairs the study’s usefulness in 
clinical practice and research.  
Lastly, the study did not achieve consensus on all statements, with 36 items (28%) failing to reach 
consensus, although 24 items from this group (i.e. 67% out of the total number of statements not 
reaching consensus) achieved near-consensus (Table 5). This reflects persisting uncertainty even 
amongst experts and specialists in the field, which can only be resolved through assessment of robust 
data from comparative studies from which higher levels of evidence can be obtained.   
 
4.4 Areas for further research 
We highlight persisting uncertainly and areas for further study. Firstly, for DAT eligibility, there is a 
need to improve determination of life expectancy more accurately and on an individualised basis. 
Presently a combination of approaches and strategies are employed, but they apply on a general 
rather than an individual level. A potential way forward may include studies exploring the creation of 
nomograms or actuarial tables integrating essential elements influencing life expectancy, such as age, 
ethnicity, social class, occupation, family history, specific co-morbidities, smoking status, and so on. 
Secondly, as our project has shown, certain thresholds remain contentious. For instance, thresholds 
beyond which disease extent on biopsy ought to lead to exclusion of patients with low-risk disease, or 
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the role of mpMRI in determining disease stage and aggressiveness as a criterion for inclusion or 
exclusion into DAT programmes, require data from prospective, well-designed studies, incorporating 
diagnostic accuracy elements and allowing synthesis of evidence regarding clinical effectiveness.  In 
particular, the definition of ‘high disease extent’ based on biopsy characteristics remains problematic, 
although there was consensus on its importance. The role of a negative confirmatory biopsy was also 
not adequately explored in our study and hence deserves further study. In addition, since decision-
making for clinicians and patients regarding DAT should be individualised, there is a need to better 
understand how the complex interaction between multiple factors influences decision-making, 
especially in terms of relative weighting placed on different variables and their trade-offs; this could 
be explored through studies utilising discrete choice experiments. [22] In terms of monitoring and 
follow-up, there was no consensus regarding the role of per-protocol mpMRI nor per-protocol repeat 
biopsies (i.e. untriggered), nor on its frequency and timing. The lack of consensus on the need for 
protocol-mandated (i.e. untriggered) repeat biopsies is particularly striking because many 
contemporary prospective studies on DAT do include them.    Although we found consensus regarding 
repeat biopsy being required if there was a change in mpMRI, DRE progression or PSA progression, it 
has to be acknowledged that the sensitivity of these triggers for higher grade disease remains 
unproven. The evolving role of mpMRI in detecting clinically significant disease in place of biopsy is 
promising, as are new biomarkers (reviewed in [23]), including serum markers (e.g. Prostate Health 
Index and 4K score), urinary markers (e.g. Prostate Cancer Antigen 3, or PCA3), and tissue markers 
(e.g. genomic profiling). Once data on these promising diagnostic interventions mature, future studies 
should integrate them into nomograms predicting the probability of reclassification. In addition, given 
the current heterogeneity in practice, there is a need to standardise the risk categories and follow-up 
strategies in large prospective studies.  Lastly, the findings from our study will improve and direct the 
standardisation of undertaking DAT in routine clinical practice and research. Clinicians should use 
them to carefully design their DAT protocols such that comparative clinical effectiveness data can be 
prospectively collected, and the results audited regularly.  Researchers should follow our guidance 
and perform clinical trials or prospective cohort studies comparing different DAT protocols against 
each other and against immediate curative interventions.       
 
5. Conclusions 
The EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel, in partnership with other leading 
guideline authorities and patient advocacy organisations (Appendix 1), undertook an ambitious 
project using a novel and transparent approach in this setting to develop consensus statements for all 
domains relating to DAT to standardise clinical practice and research. Protocol-driven, robust and 
transparent methods were utilised.  Consensus was achieved on 93 out of 129 statements (72%), 
covering the domains of criteria for patient selection, inclusion and exclusion (including patient and 
disease characteristics, imaging criteria, and type of biopsies), nature and timing of investigations and 
assessments during period of monitoring and follow-up (including PSA measurements, clinical 
examination, repeat imaging and repeat biopsies), criteria and thresholds for reclassification and 
change in management, and type of outcome measures which should be prioritised. The findings will 
guide and inform routine clinical practice and research by being incorporated into guidelines issued 
by the EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel and partner organisations, until 
higher levels of evidence emerge through prospective comparative studies and clinical trials. 
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